Latest Reimbursement News

PainChek has secured A$5.5 million via convertible notes to accelerate its US sales expansion and strengthen working capital amid key commercial milestones.

Adherium Limited plans a 1-for-100 share consolidation pending shareholder approval, aiming to reduce share count and enhance marketability.

Cleo Diagnostics has laid out a clear U.S. reimbursement pathway for its ovarian cancer test, leveraging an existing CPT code to enable early market entry and data collection ahead of FDA clearance.

Evergold Minerals has kicked off a 3,000m reverse circulation drilling campaign at its Mt Monger Gold Project, aiming to confirm high-grade gold mineralisation at Duchess of York and test a newly defined intrusive-related target at Gladiator.

SDI Limited's acquisition by Beijing Guoci's subsidiary advances with ASIC registration of the scheme booklet and court approval to convene a shareholder meeting. The all-cash offer at a 53–58% premium awaits shareholder and final court approval.

Lumos Diagnostics advances US commercial rollout of FebriDx with positive reimbursement data and expanded urgent care adoption ahead of the 2027/28 flu season.

Vitasora has launched its proprietary vCare EMR platform, cutting SaaS costs by over 90% and nearly doubling patient enrolments in April. The company targets cashflow breakeven in H2 2026 as enrolment momentum builds.

Emyria has launched its first Empax clinic in Victoria on schedule, establishing a new clinical hub with trained staff and dual reimbursement pathways to support growth.

AVITA Medical reported a 4% revenue increase in Q1 2026 with a narrowed net loss, underpinned by a new BARDA contract and promising Cohealyx clinical data. Leadership changes and regulatory approvals support a confident outlook.

Pacific Edge edges closer to a Medicare breakthrough with a draft Local Coverage Determination proposing coverage for its Cxbladder Triage and Triage Plus tests, potentially unlocking reimbursement for over 66 million US patients.

Worley unveils a medium-term growth strategy through FY30 focused on expanding full project delivery, investing $70 million in AI, and leveraging strategic partnerships amid near-term geopolitical challenges.

Pacific Edge launches a NZ$6 million retail share offer at NZ$0.17 per share following a NZ$25.4 million institutional placement, aiming to strengthen its balance sheet and support Medicare reimbursement efforts for its bladder cancer diagnostics.